Stanislav Šutovský, Patrik Gulač, Peter Turčáni
Alzheimer’s disease (AD) is defined as a clinic-pathological entity. Since the first description made by Alois Alzheimer,
AD has overcome a complicated development. Primary diagnostic criteria were worked out in 1984 and those reflected
the contemporary level of knowledge. Biomarkers and neuroimaging were not included in the protocol. This
clinical definition and diagnostic criteria were gradually overcome and there has been an increasing need for redefinition
and a new clinical concept. Recent progress in the use of reliable biomarkers has stimulated a development
of new research criteria that reconceptualise the diagnosis both around specific pattern of cognitive changes as well
as biological evidence of Alzheimer’s pathology. Simultaneously with the new lexicon has been developed new insight
for the therapy as well. Despite the fact that contemporary therapy is ideologically obsolete, and has no disease
modifying effect, it is the only registered therapy. Disease modifying therapy becomes the reality of the clinical
trials. Despite of significant progress its clinical efficacy does not meet the expectations. In this paper we try to
summarise newly revised diagnostic concept with regard to new therapeutic approaches.